
Glenmark Pharmaceuticals Ltd. share price
NSE: GLENMARK · Healthcare
₹2,632.90 -0.27%
Closing price data, updated 17 Nov 2026. 52-week range: -3.0% from high, +45.7% above low.
Price₹2,632.90
Market cap₹74,307 Cr
P/E51.2
P/B6.63
ROE14.1%
ROCE16.2%
Debt / equity0.06
Dividend yield0.00%
EPS₹51.42
Book value₹397.29
Operating margin24.1%
Dipscan score53 / 100
Share: WhatsAppX / TwitterTelegram
Glenmark Pharmaceuticals Ltd. shareholding pattern
As of Sep 2026: Promoters 46.65%, FIIs 21.51%, DIIs 17.64%, Government 0.04%, Public 10.44%, Others 3.73%.
| Holder | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 |
|---|---|---|---|---|---|---|
| Promoters | 46.65% | 46.65% | 46.65% | 46.65% | 46.65% | 46.65% |
| FIIs | 21.51% | 20.89% | 20.34% | 19.20% | 20.73% | 20.62% |
| DIIs | 17.64% | 18.60% | 19.29% | 20.09% | 18.61% | 17.64% |
| Government | 0.04% | 0.04% | 0.04% | 0.04% | 0.04% | 0.04% |
| Public | 10.44% | 10.60% | 10.32% | 10.77% | 10.81% | 11.69% |
| Others | 3.73% | 3.21% | 3.36% | 3.26% | 3.16% | 3.37% |
| No. of Shareholders | 208,414 | 211,418 | 196,105 | 201,584 | 198,789 | 190,210 |
As filed by the company with the exchanges.
Returns
| 1 day | 1 week | 1 month | 3 months | 6 months | 1 year |
|---|---|---|---|---|---|
| -0.27% | +1.66% | +17.23% | +13.49% | +12.49% | +44.88% |
Growth
| Sales growth, 3 years | +13.5% |
| Sales growth, 5 years | – |
| Profit growth, 3 years | +66.1% |
| Profit growth, 5 years | – |
| Latest quarter sales vs last year | -30.8% |
| Latest quarter profit vs last year | -56.8% |
Strengths and weaknesses
Strengths
- Company has reduced debt.
- Company has delivered good profit growth of 19.4% CAGR over last 5 years
Weaknesses
- The company has delivered a poor sales growth of 9.19% over past five years.
- Company has a low return on equity of -3.28% over last 3 years.
- Debtor days have increased from 85.2 to 107 days.
- Working capital days have increased from 41.2 days to 80.5 days
Peers in Healthcare
| Company | Price | Market cap | P/E | ROE | 1 year |
|---|---|---|---|---|---|
| Sun Pharmaceutical Industries | ₹1,867.50 | ₹4,48,076 Cr | 40.9 | 14.7% | +8.8% |
| Divi's Laboratories Ltd. | ₹11,080.00 | ₹2,94,139 Cr | 87.5 | 16.2% | +69.4% |
| Torrent Pharmaceuticals Ltd. | ₹4,691.20 | ₹1,78,438 Cr | 84.0 | 27.1% | +22.6% |
| Apollo Hospitals Enterprise Lt | ₹8,771.00 | ₹1,26,114 Cr | 56.2 | 21.9% | +16.9% |
| Laurus Labs Ltd. | ₹2,220.00 | ₹1,19,949 Cr | 89.5 | 18.2% | +125.2% |
| Zydus Lifesciences Ltd. | ₹1,192.00 | ₹1,18,902 Cr | 28.4 | 19.7% | +27.0% |
| Dr. Reddy's Laboratories Ltd. | ₹1,377.90 | ₹1,14,778 Cr | 41.0 | 12.1% | +13.7% |
| Cipla Ltd. | ₹1,394.50 | ₹1,12,658 Cr | 38.9 | 11.8% | -8.0% |
Frequently asked questions
What is the share price of Glenmark Pharmaceuticals Ltd.?
Glenmark Pharmaceuticals Ltd. (GLENMARK) last closed at ₹2,632.90 (-0.27% on the day).
What is the market cap of Glenmark Pharmaceuticals Ltd.?
About ₹74,307 Cr.
What is the P/E ratio of Glenmark Pharmaceuticals Ltd.?
The price-to-earnings ratio is 51.2, and return on equity is 14.1%.
Figures are calculated from company results and exchange prices and are for information only.